Research and Markets: Asthma: Modern Therapeutic Targets

Research and Markets: Asthma: Modern Therapeutic Targets

Research and Markets has announced the addition of the “Asthma: Modern Therapeutic Targets” book to their offering.

The care of an increasing number of adult and child patients with asthma has become a major task for clinicians, and a growing concern for public health physicians and health care administrators. At the same time, and in response to this situation, a considerable effort is being made in basic and clinical research to develop new treatments. This book looks into the future and assesses the possibilities of a number of new therapies for asthma under exploration and development. A group of distinguished international authors examine the potential of new agents working on various targets that are currently under evaluation, including autocoids and their inhibitors, enzyme-inhibitors, sensory nerves and sensory neuropeptides, and receptors in immunology Asthma: Modern Therapeutic Targets provides physicians with an appreciation of the future directions of treatment. It provides clinical pharmacologists and researchers with an up-to-date insight into advances in this exciting field. This book will also be a valuable tool for researchers in the pharmaceutical industry.

Benefits:

* Presents a comprehensive review of current treatment options
* Latest guidelines on clinical management reviewed from an international perspective
* Provides background on pharmacology and mechanisms of drug action
* Provides a key resource for individual patient care

Readership:

* Specialists in respiratory medicine, allergy and immunology
* General physicians
* Clinical pharmacologists
* Doctors in training

Key Topics Covered:

Section I: Autocoids and their receptors in airway diseases

* Adenosine receptors: novel molecular targets in asthma
* The role of transforming growth factors in asthma and their potential as a target for therapy
* The role of transcription factors in asthma: can we modify them for therapeutic purposes?
* Is IKK a feasible therapeutic target for allergic asthma?

Section II: Enzyme inhibitors

* Protease-activated receptors: targets for therapeutic intervention in asthma
* Nitric oxide synthase as a therapeutic target in asthma
* Metalloproteinases and asthma: untried potential for new therapeutic strategies

Section III: Sensory nerves and sensory neuropeptides

* Sensory neuropeptides as innovative targets in asthma
* Rationale for vanilloid receptor 1 antagonist-based therapies in asthma

Section IV: Receptors in immunology

* Anticytokines and cytokines as asthma therapy
* Tumour necrosis factor alpha and asthma
* Are chemokines viable targets for asthma?
* Antagonism of the chemokine receptor CCR3 as a potential therapeutic treatment for asthma

Author:

* R Polosa, Presidio Ospedaliero Ascoli-Tomaselli, Catania, Italy
* ST Holgate, Southampton General Hospital, Southampton, UK

For more information visit http://www.researchandmarkets.com/research/a7c5bf/asthma_modern_the

Contacts

Research and Markets
Laura Wood, Senior Manager,
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Black Rice Consumption May Lead To Anti-Inflammatory Benefits – BETTER Health Research


TheMedGuru

Black Rice Consumption May Lead To Anti-Inflammatory Benefits
BETTER Health Research
Previous studies have shown that black rice bran contained anti-inflammatory compounds, which helps prevent allergies, asthma and other related illnesses.
Black rice may relieve inflammation caused by allergies, asthmaSify
Allergy, asthma inflammation can be cured by black rice: Studyinfocera
Black Rice may be Helpful in Treating Chronic Inflammatory DiseasesTopNews United Kingdom
Investor’s Business Daily –HealthJockey.com –TheMedGuru
all 31 news articles »

View full post on asthma – Google News

Childhood Asthma and Antibiotic use Link?

Research team investigates whether antibiotic use triggers childhood asthma and allergies

Study looks at how intestinal bacteria changes in newborns after babies take antibiotics, and whether changes trigger certain medical conditions

A cross-Canada team of medical researchers suspects that giving antibiotics to infants in their first year of life may be the underlying trigger that causes asthma and allergies to develop later in childhood.

The researchers, from five Canadian universities, are conducting a major, $2.5-million study on how intestinal bacteria changes in newborns after the babies take antibiotics, and whether those changes trigger certain medical conditions in children. The researchers include microbiologists, epidemiologists and immunologists.

Anita Kozyrskyj, who is co-lead investigator in this new federally funded study, demonstrated in a pilot study that infants who receive antibiotics by three months of age have changes in their microbiota.

“The number of different kinds of bacteria is less,” says Kozyrskyj, a researcher in the Faculty of Medicine & Dentistry at the University of Alberta.

“Now the question is: does antibiotic use early in life change the microbiota in the intestines of children? And are these changes associated with the development of asthma and allergies in children? We are hoping to specifically pinpoint which ‘bad’ bacteria it is that is causing asthma.”

Everyone has “good” intestinal bacteria, known as microbiota, to help absorb nutrients and protect against harmful bacteria. No one is born with this; it develops throughout the first year of life. Normal development of the microbiota can be affected by various factors such as caesarean-section delivery and infant diet and medication use. By one year of age, more than 50 per cent of Canadian infants will receive an antibiotic prescription.

Studies have shown that antibiotics affect the microbiota. As well, composition of microbiota in children who have allergies is different than the microbiotia in children who don’t suffer from allergies, as demonstrated by previous research studies.

Her research will zero in on antibiotic use in the first year of life and will be conducted through a research group called SyMBIOTA, or Synergy in Microbiota Research. The SyMBIOTA team includes researchers Piush Mandhane, Dean Befus, Radha Chari and Catherine Field.

Her colleagues from the University of Toronto, co-principal investigator James Scott and researcher David Guttman, will look at the composition of microbiota from fecal samples from children aged three months and at one year; this will involve about 2,500 babies from across the Prairies and the West Coast. By extracting DNA from these samples, researchers will be able to identify the bacteria that are present in microbiota.

Tatiana Celemin’s four-month-old baby, Sara, is taking part in the research study. Celemin’s son has asthma and that is one of the key reasons the family wanted to get involved with the study—to help researchers find out more about the condition.

“Even if it doesn’t have an impact on Sara, I think it’s important for the medical research to be there to hopefully impact future generations of children.”

This research is funded by the Canadian Institutes of Health Research and the AllerGen Network Centres of Excellence.

Kozyrskyj, an epidemiologist, is an associate professor of pediatrics at the U of A, and the Women and Children’s Health Research Institute research chair in maternal-child health and the environment.

Genetic Variants May Help Advance Asthma Treatments – BETTER Health Research


TheMedGuru

Genetic Variants May Help Advance Asthma Treatments
BETTER Health Research
Different genetic changes may increase one's likelihood of developing asthma, according to a study published in the New England Journal of Medicine.
Asthma linked to genetic variantsNursing in Practice
Drugs 'could target asthma genes'Nursing Times
Gene mapping apparently sheds light on childhood asthmaHealthJockey.com
Medscape –News-Medical.net –BusinessWeek
all 89 news articles »

View full post on asthma – Google News